Oppenheimer Research Analysts Cut Earnings Estimates for Trevi Therapeutics, Inc. (NASDAQ:TRVI)
Oppenheimer Research Analysts Cut Earnings Estimates for Trevi Therapeutics, Inc. (NASDAQ:TRVI)
Trevi Therapeutics, Inc. (NASDAQ:TRVI – Get Rating) – Research analysts at Oppenheimer cut their FY2022 earnings per share (EPS) estimates for shares of Trevi Therapeutics in a research report issued to clients and investors on Monday, November 14th. Oppenheimer analyst L. Gershell now anticipates that the company will post earnings per share of ($0.51) for the year, down from their prior estimate of ($0.49). The consensus estimate for Trevi Therapeutics' current full-year earnings is ($0.55) per share. Oppenheimer also issued estimates for Trevi Therapeutics' Q4 2022 earnings at ($0.09) EPS, Q1 2023 earnings at ($0.09) EPS, Q2 2023 earnings at ($0.10) EPS, Q3 2023 earnings at ($0.10) EPS, Q4 2023 earnings at ($0.11) EPS, FY2023 earnings at ($0.41) EPS, FY2024 earnings at ($0.44) EPS, FY2025 earnings at ($0.39) EPS and FY2026 earnings at ($0.35) EPS.
特雷維治療公司(納斯達克:TRVI-GET評級)-奧本海默的研究分析師在11月14日星期一發布給客户和投資者的一份研究報告中下調了他們對特雷維治療公司2022財年每股收益(EPS)的預期。奧本海默分析師L.Gershell現在預計,該公司今年的每股收益將為0.51美元,低於此前預測的0.49美元。對Trevi治療公司目前全年收益的普遍估計為每股0.55美元。奧本海默還發布了對Trevi治療公司2022年第四季度每股收益(0.09美元)、2023年第一季度每股收益(0.09美元)、2023年第二季度每股收益(0.10美元)、2023年第三季度每股收益(0.10美元)、2023年第四季度每股收益(0.11美元)、2023財年每股收益(0.41美元)、2024財年每股收益(0.44美元)、2025財年每股收益(0.39美元)和2026財年每股收益(0.35美元)的預期。
Trevi Therapeutics (NASDAQ:TRVI – Get Rating) last announced its quarterly earnings results on Thursday, November 10th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.03.
特雷維治療公司(納斯達克代碼:TRVI-GET Rating)上一次公佈季度收益是在11月10日星期四。該公司公佈了該季度每股收益(EPS)(0.12美元),比普遍預期的(0.15美元)高出0.03美元。
Trevi Therapeutics Stock Performance
Trevi Treeutics股票表現
Shares of NASDAQ TRVI opened at $2.14 on Thursday. The company has a quick ratio of 5.18, a current ratio of 8.70 and a debt-to-equity ratio of 0.03. The business's 50 day moving average is $2.06 and its two-hundred day moving average is $2.65. The company has a market cap of $94.31 million, a P/E ratio of -2.74 and a beta of 0.75. Trevi Therapeutics has a 12 month low of $0.46 and a 12 month high of $4.68.
週四,納斯達克天貓的股價開盤報2.14美元。該公司的速動比率為5.18,流動比率為8.70,債務權益比率為0.03。該業務的50日移動均線切入位在2.06美元,200日移動均線切入位在2.65美元。該公司市值為9431萬美元,市盈率為-2.74,貝塔係數為0.75。Trevi Treeutics的12個月低點為0.46美元,12個月高位為4.68美元。
Hedge Funds Weigh In On Trevi Therapeutics
對衝基金對特雷維治療公司的看法
Large investors have recently made changes to their positions in the company. Commonwealth Equity Services LLC bought a new stake in Trevi Therapeutics in the 1st quarter valued at about $33,000. Virtu Financial LLC bought a new position in shares of Trevi Therapeutics in the first quarter worth $44,000. Acuta Capital Partners LLC purchased a new position in Trevi Therapeutics in the second quarter worth $98,000. State Street Corp purchased a new stake in Trevi Therapeutics during the first quarter valued at about $81,000. Finally, Jump Financial LLC bought a new position in Trevi Therapeutics in the third quarter worth about $66,000.
大型投資者最近對他們在該公司的頭寸進行了調整。英聯邦股權服務有限責任公司在第一季度購買了Trevi治療公司的新股份,價值約33,000美元。Virtu Financial LLC在第一季度購買了價值44,000美元的Trevi Treeutics股票的新頭寸。Acuta Capital Partners LLC在第二季度購買了Trevi治療公司的一個新頭寸,價值98,000美元。道富集團在第一季度購買了Trevi治療公司的新股份,價值約81,000美元。最後,Jump Financial LLC在第三季度購買了Trevi治療公司的一個新頭寸,價值約6.6萬美元。
About Trevi Therapeutics
特雷維治療公司簡介
(Get Rating)
(獲取評級)
Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis.
Trevi治療公司是一家臨牀階段的生物製藥公司,專注於Haduvio的開發和商業化,以治療嚴重的神經介導性疾病。該公司正在開發Haduvio,這是一種納布芬的口服緩釋製劑,處於IIb/III期臨牀試驗,用於治療特發性肺纖維化患者的慢性瘙癢和慢性咳嗽。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Trevi Therapeutics (TRVI)
- MarketBeat: Week in Review 11/14 – 11/18
- Target's Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Does ASML's November Rally Have Staying Power?
- Verra Mobility Stock Has Returned Back to the Station
- 免費獲取StockNews.com關於特雷維治療公司(TRVI)的研究報告
- MarketBeat:回顧一週11/14-11/18
- 目標的雙重底部可能剛剛得到確認
- 美聯儲能漲到多高?如何進行交易
- ASML的11月拉力賽有後勁嗎?
- Verra移動庫存已返回空間站
Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Trevi治療日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Trevi治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。